Beth Ann Schimel, PharmD

#1 rule of new technology in medicine for the US = What’s the payment model? = Most traditional and reliable payment model is still fee for service codes. It appears we’ll get new codes from the American Medical Association that could mean more #RemotePatientMonitoring reimbursement by 2025 - If the American Medical Association approves new changes and Medicare and private payers follow suit, providers that expand their remote patient monitoring programs to fit the new codes will gain the most benefits for their patients and clinics https://lnkd.in/eCcCnG8S #DigitalHealth #TransformingCare

12

2 Comments

In a new five-part video series, ABMS Portfolio Program Manager Teena Nelson, MHA, answers the “Top 5 Questions” she hears from organizations interested in becoming a Sponsor so that they can offer continuing certification credit to their physicians. Quick Question 1: What is the ABMS Portfolio Program? #HigherStandardsBetterCare #QI

16

1 Comment

Following Novo Nordisk's announcement of Levemir insulin discontinuation in the U.S., we surveyed our database of individuals with diabetes to gauge interest in transitioning from MDI to insulin pumps. Here are the findings from our 24-hour pulse survey: - 21% are considering switching to insulin pumps - 68% prefer switching to another long-acting insulin And for more context, here are some of the written responses we collected: "I want to talk to my doctor before deciding." "I just started taking insulin, I am unsure that my insurance would cover a pump. Otherwise, I would use a pump." "I will switch to a different brand just in case I don't have enough pump supplies." "I was happy with my regimen. But after so many years, I'm wondering if this is the time to try either Tandem or Omnipod instead (it's hard to decide which)." This year, our team dove deep into GLP-1 RA trends, including why patients start, stop, and switch GLP-1 and SGLT2-I treatments. We compiled all of our findings into a comprehensive report that we are offering FREE for a limited time. Download the full report here: https://lnkd.in/eRPYVXFF

16

💡Free Virtual Event 👉🏼 Futureproofing Biosimilars and Expanding Patient Access: Discuss the U.S. biosimilars market, the value biosimilars provide to patients, how these medicines fit into the health care system — and what needs to be done to advance adoption. #PatientAccess #Healthcare #Biosimiliars #HealthData #HealthcareSystem

2

Has Regeneron been successful with EYLEA HD® (aflibercept) Injection HCP as the patent for regular Eylea expires in June 2027? There will be 5 biosimilars, including 2 labeled as interchangeable, available next year. Regeneron reported their earnings yesterday and below 👇 you see their quarterly sales of both regular Eylea and HD. Sales of Eylea HD grew 30% Q over Q from $304M to $392M ($40M of Q3 is due to increased distributor inventories). But is that enough? The problem is over $1.1 B or 2/3 of Eylea sales remain in regular Eylea. With loss of its patent, Eylea will lose its pricing power, its moat, entirely. It will become one of 6 equivalent commodities. Basic economics dictates that without a moat, competition will drive prices to marginal costs and the profits to zero. The stock market seems to agree with my analysis as $REGN stock is down 10% overnight and 30% in 2 months. In the end, patients will be the winners. #retina #ophthalmology #optometry

10

1 Comment

Quest Diagnostics and Allina Health have announced a significant partnership that will reshape laboratory services in Minnesota and western Wisconsin. Quest Diagnostics has entered into a definitive agreement to acquire select laboratory assets from Allina Health, aiming to enhance access to innovative and cost-effective diagnostic services in the region. This strategic move will allow Quest to expand its extensive service offerings throughout Minnesota and western Wisconsin, providing broader access to their innovative laboratory services for providers and patients. The transaction is expected to be completed in the third quarter of 2024, subject to customary regulatory reviews. Jim Davis, Chairman, CEO and President of Quest Diagnostics, emphasized the shared commitment of both organizations to deliver quality and innovative laboratory services at affordable prices. He stated, "This transaction also reflects progress in delivering on our strategy, which includes generating growth through accretive laboratory acquisitions." Dominica Tallarico,B.S., M.S.,FACHE, Chief Operations Officer for Allina Health, expressed confidence in Quest as the right partner to build upon Allina's foundation of excellence in lab services. She highlighted that this move will allow Allina Health to reinvest its non-profit resources to support its caring mission well into the future. This partnership represents a significant development in the healthcare landscape of the region. https://lnkd.in/e-kSaHiQ 📰 Stay ahead of the curve by following Practical Patient Care on LinkedIn for more industry news and insights. You can also access our latest edition here: https://lnkd.in/guUBWkRE #QuestDiagnostics #AllinaHealth #HealthcareInnovation #LaboratoryServices

4

WEBINAR ALERT: Register for this fast-approaching panel discussion on ways to overcome challenges associated with #oncology #RWD to drive better decision-making and improve #patientoutcomes. Register here: https://lnkd.in/eecGa6YD On May 29, Wendy Turenne (Aetion) will be joined by Andrew Belli (COTA) and Mark Shapiro (xCures) to discuss: - The intricacies of oncology care and the measurable outcomes captured through RWD - Critical elements for oncology, such as #biomarkers, progression and #mortality - Strategies for extracting insights from unstructured #EMR data, such as clinical #genomic data and #medicalimages From The Evidence Base® #outcomesresearch #rwe #realworldevidence #realworlddata #pharma #biopharma #regulation #regulatoryaffairs #hta #healthtechnologyassessment #healthdata #healthpolicy #clinicaldevelopment #clinicaltrials

7

Value Based Care for Nephrologists with Brian O'Dea: Insights from the CEO of NANI - Nephrology Associates Northern Illinois / Indiana. As value-based care (VBC) continues to shape the healthcare landscape, practices like NANI have positioned themselves as pioneers in adapting to this new model. CEO Brian O'Dea shared how NANI has not only embraced VBC but also thrived by focusing on patient outcomes, cost efficiency, and collaborative care. Find out more insights from the podcast here: https://lnkd.in/eFangan4 #vbc #nephrology #healthcare

4

Adial Pharmaceuticals (NASDAQ: ADIL) is pioneering a shift in addiction treatment with a genetic test, laying a foundation for precision medicine in Alcohol Use Disorder (AUD) management. This approach facilitates physician-patient dialogue, starts treatment with a test rather than a drug, and enhances patient engagement and compliance. Discover how our approach is transforming AUD treatment: https://bit.ly/4gDr0kw #PrecisionMedicine #HealthInnovation #AUDTreatment

11

1 Comment

In collaboration with our partners at cmmb, and with support from PQMD, we provide diabetes patients in Lebanon with the resources they need to manage their health. Watch to learn more. #Healthcare #DiabetesManagement #Anera #Lebanon Sean C. Carroll

51

Many innovative ideas can become obscured when communicated, which was a significant challenge for Patient Blood Management #PBM as it was introduced to benefit those suffering from #anemia, in hopes of enabling surgery without the use of donated blood upon leaving the ER (Emergency Room). The PBM educational approach supports bloodless surgical procedures. To reduce this obscurity, we are simplifying the message and increasing awareness, benefiting #researchers, manufacturers, and healthcare practitioners. Most importantly, we are enhancing the patient experience and raising public awareness. We are confident that many global organizations, healthcare providers, and blood management surgical equipment manufacturers will support our efforts as we continue to be pioneers in building a bridge of engagement for public access, which will benefit this field of medicine. Remember our medical icons, just in case one day you need direction to the OR. #Bloodlines #BBTS #Blood #SABM

6

Transparency: DEFCON 1 level: https://lnkd.in/grbq5fRP

29

3 Comments

The FDA Oncology Center of Excellence (OCE) Project 5 in 5 is a crowdsourcing initiative to ultimately identify 5 clinically relevant questions that can be answered through use of pragmatic clinical trials, using FDA-approved oncology therapies, over the next 5 years. https://lnkd.in/e2mun4uM

5

Planning for the annual Association for Value-Based Cancer Care (AVBCC) Educational Summit & Program requires the insight of leaders from across the oncology ecosystem. We would like to extend our gratitude to the following members of our AVBCC 2024 Co-Chair Committee for the time, energy, and talent they've devoted to helping us ensure we once again deliver a tremendous event for our guests: Cheryl Ann Allen, MBA, BS Pharm, Founding Partner, Curatio Scientia Advisors Sibel Blau, MD, President & CEO, QCCA, LLC, Medical Director, Northwest Medical Specialties, PLLC Mark Chassay, MD, MEd, MBA, Chief Medical Officer, Blue Cross and Blue Shield of Texas Basit Chaudhry, MD, PhD, Founder, Tuple Health Nancy Daly, MS, MPH, CEO, Conquer Cancer Ranjani Durham, Senior Vice President and Head, US Market Access, BMS Doug Flora, MD, LSSBB, FACCC, Executive Medical Director, Oncology Services, St. Elizabeth Healthcare John Fox, MD, MHA, Senior Medical Director of the Americas, Market Access, Illumina Marianne Gandee, VP, Patient Solutions & Alliances, North America Pfizer Oncology Stephen Grubbs, MD, FASCO, VP, Care Delivery, American Society of Clinical Oncology Beth Hamilton, MBA, VP, Global Oncology Market, Access and Pricing, AstraZeneca Lisa Harrison, RPh, President and General Manager, Oncology Supply, Cencora David Johnson, MD, MPH, Clinical Operating Partner, Rubicon Founders Stan Kachnowski, PhD, MPA, Director, Digital Health Program, Columbia Business School Ira Klein, MD, MBA, FACP, VP, Medical Affairs, Payer Relations, Tempus Labs, Inc. Michael Kolodziej, MD, Chief Medical Officer, Canopy Lavi Kwiatkowsky, CEO & Founder, Canopy Lucy Ruwitch Langer, MS, MD, National Medical Director, Oncology and Genomics, UnitedHealthcare Join Luh, MD, FACP, FACR, Radiation Oncologist, Providence Health William McGivney, PhD, Managing Partner, McGivney Global Advisors Kathy Oubre, MS, CEO, Pontchartrain Cancer Center Debra Patt, MD, PhD, MBA, Executive Vice President, Policy and Strategic Initiatives, Texas Oncology Alti Rahman, MHA, MBA, CSSBB, Chief Strategy and Innovation Officer, American Oncology Network Chevon Rariy, MD, Chief Health Officer, Oncology Care Partners Marc Samuels, Founder & CEO, ADVI Health Muna Tuna, US Market Pricing and Reimbursement Leader, Ernest & Young, LLP Tim Ward, Esq., President, Hercules Lalan Wilfong, MD, VP, Payer Relations and Practice Transformation, The US Oncology Network Burt Zweigenhaft, PhD, DLitt, Co-Founder AVBCC #ValueBasedCancerCare #HealthcareLeaders #OncologyCare #HealthcarePolicy #ValueBasedCare #AVBCC #OncologySummit #HealthcareConference #Cancer #Oncology

7

In their latest podcast MM+M is joined by Osama Hashmi MD MPH and Dr. Greene to discuss an important topic: the expected evolution of pharma interactions. HCP engagement is constantly evolving and brands are continually adapting. One thing stays the same — trying to connect healthcare professionals to the resources that give their patients the best access to care. Hear the expected evolution of pharma interactions from the valuable voice of the physician as they discuss the most pressing questions on pharma interaction. Listen here: https://lnkd.in/enHhW7Cu

16

Have you downloaded your copy of the HCP 101 Guide to Prebiotics? The HCP 101 Guide is a foundational resource designed to empower healthcare professionals with essential knowledge in the rapidly advancing prebiotic sector. 🔍 Inside the guide, you'll discover key topics such as: ✅ The various prebiotic types ✅ Associated benefits ✅ Regulatory considerations ✅ And much more! With a focus on clarity, this guide offers a thorough lexicon of essential Prebiotic/Microbiome terms, equipping practitioners with the foundation they need for success. The first iteration of the guide is available to download on the GPA website, with plans for expansion as new developments emerge in prebiotic research and application. The prebiotic space is growing rapidly, and knowing where to start can be tough. Download your FREE copy of the HCP 101 Guide and gain the confidence you need to make informed, gut-friendly decisions 🦠 🌐 🔗: https://lnkd.in/epE7hXtr #Prebiotics #HCP #HealthcarePractitioners #Dietitians #Microbiome Len Monheit Morgan Johnston Tim Mizones Kara Landau

5

1 Comment